Wegovy’s MASH Approval Broadens the GLP-1 Market
Wegovy’s approval in China for MASH marks a shift in how GLP-1 medicines are positioned. The category is moving from a weight-loss conversation toward integrated care for obesity, liver disease and cardiovascular risk.
5 min read
Read more